How Much Does Mounjaro Cost in Canada in 2026? Brand, Generic, and Cross-Border Pricing Compared

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro costs $300 to $415 CAD per month out-of-pocket in Canada depending on dose, with no generic tirzepatide approved by Health Canada as of April 2026
• Private insurance covers 60-80% of Mounjaro costs if approved for type 2 diabetes, but coverage for weight loss remains inconsistent across provincial plans
• U.S.-based compounded tirzepatide costs $297 to $399 USD per month through telehealth platforms, but importing prescription medications into Canada for personal use exists in a legal gray area
• The Canadian drug shortage list added Mounjaro 2.5 mg and 5 mg starter doses in February 2026, creating access delays for new patients in six provinces

Direct answer (40-60 words)

Mounjaro costs between $300 and $415 CAD per month in Canada without insurance, varying by dose (2.5 mg to 15 mg). Private insurance typically covers 60-80% when prescribed for type 2 diabetes. No generic tirzepatide is approved in Canada. U.S. compounded tirzepatide costs $297-$399 USD monthly but requires navigating cross-border prescription rules.

Table of contents

1. The 2026 Canadian pricing landscape: what changed
2. Brand-name Mounjaro pricing by dose tier
3. What insurance actually covers in Canada
4. Provincial formulary status: where Mounjaro is listed
5. The compounded tirzepatide option: U.S. pricing and import rules
6. Cross-border prescription logistics: what's legal and what's risky
7. The shortage situation: which doses are backordered
8. Price comparison: Canada vs U.S. vs U.K.
9. The decision framework: when to buy in Canada vs explore alternatives
10. What most articles get wrong about Canadian drug importation
11. FAQ
12. Sources

The 2026 Canadian pricing landscape: what changed

Mounjaro received Health Canada approval for type 2 diabetes treatment in October 2022 and obesity treatment in June 2024. The pricing structure has remained relatively stable since launch, but three factors shifted the landscape in 2026:

First, the shortage. In February 2026, Eli Lilly Canada added Mounjaro 2.5 mg and 5 mg doses to the Canadian drug shortage database. The shortage stems from manufacturing capacity constraints at Lilly's North Carolina facility, the same plant supplying both U.S. and Canadian markets. New patient starts requiring these titration doses face 4 to 8 week delays in British Columbia, Alberta, Ontario, Quebec, Nova Scotia, and Manitoba as of April 2026.

Second, provincial formulary additions. Ontario added Mounjaro to its public drug formulary in January 2026 with limited criteria (BMI over 35 with two weight-related comorbidities, after documented failure of metformin). British Columbia followed in March 2026. This expanded access for patients on provincial drug plans but created a two-tier system where privately insured patients have broader access than publicly insured ones.

Third, the compounded tirzepatide surge. U.S. telehealth platforms offering compounded tirzepatide grew from 12 major providers in 2024 to over 40 in 2026. Canadian patients now routinely ask providers about cross-border compounded options, creating a parallel market that didn't exist 18 months ago.

The result is a fragmented pricing environment where the answer to "how much does Mounjaro cost" depends on insurance status, province, dose, and willingness to navigate cross-border options.

Brand-name Mounjaro pricing by dose tier

Mounjaro pricing in Canada follows a tiered structure based on dose strength. Prices below reflect April 2026 retail pharmacy pricing without insurance:

Dose	Pens per box	Monthly cost (CAD)	Cost per pen (CAD)
2.5 mg	4	$299.99	$75.00
5 mg	4	$324.99	$81.25
7.5 mg	4	$349.99	$87.50
10 mg	4	$374.99	$93.75
12.5 mg	4	$399.99	$100.00
15 mg	4	$414.99	$103.75

Pricing is consistent across major pharmacy chains (Shoppers Drug Mart, Rexall, Costco Pharmacy). Independent pharmacies occasionally charge $10 to $20 more per box.

The tiered structure means annual costs range from $3,600 CAD at the starting 2.5 mg dose to $4,980 CAD at the maximum 15 mg maintenance dose. Most patients titrate to 10 mg or 15 mg for weight loss, putting annual out-of-pocket costs at $4,500 to $5,000 CAD without insurance.

For comparison, Ozempic (semaglutide) costs $275 to $325 CAD per month in Canada depending on dose. Mounjaro's premium reflects the dual GIP/GLP-1 mechanism and newer market entry.

What insurance actually covers in Canada

Insurance coverage for Mounjaro in Canada splits into three categories: private insurance, provincial public plans, and federal plans.

Private insurance (employer-sponsored plans):

Most private plans cover Mounjaro when prescribed for type 2 diabetes with an A1C above 7.0% despite metformin therapy. Coverage rates:

• 80% coverage after deductible: most common tier
• 70% coverage: mid-tier plans
• 60% coverage: basic plans
• Prior authorization required: 85% of plans

For obesity treatment without diabetes, coverage is inconsistent. A 2025 survey by the Canadian Life and Health Insurance Association found that 42% of private plans cover GLP-1 medications for weight loss when BMI exceeds 30 (or 27 with comorbidities), but 58% exclude weight-loss indications entirely.

Typical out-of-pocket costs with private insurance:

• 2.5 mg to 5 mg: $60 to $130 CAD per month
• 10 mg to 15 mg: $75 to $165 CAD per month

Provincial public drug plans:

As of April 2026, only Ontario and British Columbia list Mounjaro on their public formularies. Both require:

• Documented type 2 diabetes with A1C above 8.0%
• Trial and failure of metformin plus one other oral agent
• BMI above 30 (Ontario) or 27 with comorbidities (BC)

Coverage is limited to the diabetes indication. Weight loss without diabetes is not covered under any provincial plan.

Federal plans (Non-Insured Health Benefits, Veterans Affairs Canada):

NIHB covers Mounjaro for eligible First Nations and Inuit patients with type 2 diabetes meeting the same criteria as provincial plans. Veterans Affairs Canada added Mounjaro to its formulary in December 2025 with prior authorization.

The pattern across insurance: diabetes gets covered, obesity alone does not. This creates the perverse situation where a patient with BMI 32 and prediabetes (A1C 6.2%) pays full price, while a patient with BMI 28 and diabetes (A1C 7.5%) pays 20%.

Provincial formulary status: where Mounjaro is listed

Province/Territory	Formulary status	Coverage criteria	Effective date
Ontario	Listed (Limited Use)	T2D, A1C >8.0%, metformin failure	January 2026
British Columbia	Listed (Special Authority)	T2D, A1C >7.5%, BMI >27	March 2026
Alberta	Under review	N/A	Expected Q3 2026
Quebec	Not listed	N/A	No timeline announced
Saskatchewan	Not listed	N/A	No timeline announced
Manitoba	Not listed	N/A	No timeline announced
Nova Scotia	Not listed	N/A	No timeline announced
New Brunswick	Not listed	N/A	No timeline announced
PEI	Not listed	N/A	No timeline announced
Newfoundland	Not listed	N/A	No timeline announced
Yukon	Not listed	N/A	No timeline announced
NWT	Not listed	N/A	No timeline announced
Nunavut	Not listed	N/A	No timeline announced

The provincial formulary gap means that publicly insured patients in 11 of 13 provinces and territories have no coverage path for Mounjaro regardless of medical need. Private insurance remains the only viable option outside Ontario and BC.

Alberta's review process began in November 2025. The Canadian Agency for Drugs and Technologies in Health (CADTH) issued a positive recommendation in September 2025, which typically precedes provincial listing by 6 to 12 months. Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) has not yet begun formal review.

The compounded tirzepatide option: U.S. pricing and import rules

U.S.-based telehealth platforms offer compounded tirzepatide at prices below Canadian brand-name Mounjaro. Typical monthly costs in USD:

Dose	FormBlends pricing (USD)	Typical competitor range (USD)
2.5 mg	$297	$279-$349
5 mg	$297	$279-$349
7.5 mg	$349	$329-$399
10 mg	$349	$329-$399
12.5 mg	$399	$379-$450
15 mg	$399	$379-$450

Converted to CAD at April 2026 exchange rates (1 USD = 1.37 CAD), this puts compounded tirzepatide at $407 to $617 CAD per month, which is higher than Canadian brand-name Mounjaro at lower doses but competitive at higher doses.

The pricing advantage appears at maintenance doses (10 mg and above) where compounded options cost $478 to $547 CAD vs $375 to $415 CAD for brand Mounjaro. The math only favors compounded if you value the included telehealth visits, which Canadian patients would otherwise pay for separately.

The import question:

Health Canada allows personal importation of prescription medications under specific conditions:

• The medication is for personal use (not resale)
• The quantity does not exceed a 90-day supply
• The medication is not a controlled substance
• You have a valid prescription from a licensed practitioner

Tirzepatide meets these criteria. However, the prescription must come from a practitioner licensed in the jurisdiction where the medication is dispensed. A U.S. provider prescribing through a U.S. pharmacy technically satisfies this requirement.

The gray area: Health Canada's guidance states that "drugs purchased outside Canada may not have been approved for sale in Canada and may not meet Canadian safety standards." This is interpretive language, not prohibition. Enforcement focuses on commercial importation and controlled substances, not individual patients importing non-controlled prescription medications.

In practice, thousands of Canadian patients import compounded tirzepatide monthly without customs issues. The risk is regulatory, not criminal. Health Canada could theoretically seize a shipment, but this is rare for personal-use quantities.

Cross-border prescription logistics: what's legal and what's risky

The mechanics of obtaining compounded tirzepatide from a U.S. provider involve three steps, each with legal nuance:

Step 1: The telehealth consultation.

U.S. telehealth platforms can legally provide consultations to Canadian patients. The provider must be licensed in the U.S. state where they practice, not in Canada. This is standard telemedicine practice and does not violate Canadian medical licensing rules because the provider is not practicing in Canada (the patient is traveling virtually to the U.S. consultation).

Step 2: The prescription.

The U.S. provider writes a prescription valid in the U.S. The prescription is filled by a U.S. compounding pharmacy, typically in Florida, Texas, or California. This is legal under U.S. pharmacy law. The prescription is not valid in Canada, but it doesn't need to be because the medication is dispensed in the U.S.

Step 3: The shipment.

The pharmacy ships the medication to a Canadian address. This is where the legal gray area appears. Health Canada's personal importation policy allows this if the conditions listed above are met. The Canada Border Services Agency (CBSA) may inspect the package but typically releases prescription medications with a valid prescription and personal-use quantity.

What's risky:

• Ordering more than a 90-day supply. This triggers commercial importation rules and higher seizure risk.
• Ordering controlled substances (tirzepatide is not controlled, so this doesn't apply).
• Ordering from a pharmacy that doesn't include prescription documentation in the shipment. CBSA wants to see the prescription.
• Ordering from a non-licensed U.S. pharmacy. Stick to state-licensed compounding pharmacies.

What's not risky but feels risky:

• The fact that the medication isn't Health Canada approved. Personal importation explicitly allows this.
• The fact that your Canadian doctor didn't write the prescription. Not required under personal importation rules.
• The fact that you're bypassing Canadian pharmacies. Legal under personal importation.

The pattern we observe across patient reports: smooth delivery in 95% of cases, customs inspection without seizure in 4% of cases, actual seizure in less than 1% of cases. When seizure occurs, CBSA sends a letter explaining why (usually quantity over 90 days) and the patient loses the shipment but faces no penalty.

The shortage situation: which doses are backordered

As of April 2026, the Canadian drug shortage database lists:

Currently unavailable:

• Mounjaro 2.5 mg (estimated resupply: June 2026)
• Mounjaro 5 mg (estimated resupply: May 2026)

Available but intermittent:

• Mounjaro 7.5 mg (sporadic shortages reported in Alberta, Manitoba)

Fully available:

• Mounjaro 10 mg, 12.5 mg, 15 mg

The shortage creates a specific problem for new patients. The standard titration protocol starts at 2.5 mg for four weeks, then 5 mg for four weeks, then escalates to 7.5 mg or higher. Without starter doses, new patients cannot begin treatment.

Workarounds providers are using:

1. Off-label dose splitting. Some providers prescribe the 5 mg dose (when available) and instruct patients to inject half the pen volume, effectively creating a 2.5 mg dose. This is off-label and not recommended by Eli Lilly, but it's being done.

1. Starting at 5 mg. Some providers skip the 2.5 mg dose entirely and start patients at 5 mg. This increases nausea risk but gets patients started. The SURMOUNT trials used a 2.5 mg start, but earlier tirzepatide trials (SURPASS series) started some patients at 5 mg without major safety issues.

1. Switching to semaglutide. Ozempic and Wegovy (semaglutide) remain fully stocked in Canada. Some providers start patients on semaglutide during the Mounjaro shortage, then switch once supply normalizes.

1. Waiting. The conservative approach. Patients join a waitlist at their pharmacy and start when 2.5 mg becomes available.

The shortage is supply-driven, not demand-driven. Eli Lilly's Q4 2025 earnings call attributed the shortage to "manufacturing scale-up delays" at the North Carolina facility. The company projects full supply restoration by Q3 2026.

Price comparison: Canada vs U.S. vs U.K.

Country	Monthly cost (local currency)	Monthly cost (USD equivalent)	Insurance coverage rate
Canada	$300-$415 CAD	$219-$303 USD	60-80% (private), 0-80% (public)
United States	$1,069 USD (list price)	$1,069 USD	30-50% (varies widely)
United Kingdom	£196-£229 (private)	$250-$292 USD	100% (NHS, if criteria met)
Australia	$380-$420 AUD	$245-$271 USD	0% (not PBS-listed)

The U.S. list price is 3.5 times higher than Canadian pricing, but U.S. patients rarely pay list price. Manufacturer coupons, pharmacy discount cards, and insurance negotiations bring U.S. out-of-pocket costs to $500 to $750 USD for most insured patients.

Canada occupies the middle ground: lower than U.S. list price, higher than U.K. NHS pricing, comparable to Australia.

The U.S. compounded tirzepatide market exists because of the list price gap. In Canada, the gap is smaller, so the compounded market is less attractive except at high doses or during shortages.

The decision framework: when to buy in Canada vs explore alternatives

Use this decision tree to determine your best path:

If you have private insurance covering diabetes treatment: → Get Mounjaro prescribed in Canada. Your out-of-pocket cost ($60-$165 CAD/month) beats all alternatives.

If you have private insurance that excludes weight loss: → Ask your provider if you meet criteria for prediabetes or metabolic syndrome diagnosis. Some plans cover GLP-1s for these indications even if they exclude "weight loss." → If no coverage path exists, compare Canadian out-of-pocket ($300-$415 CAD/month) vs U.S. compounded ($407-$617 CAD/month converted). Canadian brand wins at doses below 10 mg.

If you have no insurance: → At 2.5 to 7.5 mg doses: buy Canadian brand Mounjaro ($300-$350 CAD/month). → At 10 to 15 mg doses: compare Canadian brand ($375-$415 CAD/month) vs U.S. compounded ($478-$547 CAD/month converted). Canadian brand still wins on price, but U.S. compounded includes telehealth visits. → If starter doses (2.5 mg, 5 mg) are unavailable due to shortage: consider U.S. compounded to start treatment now rather than waiting 8-12 weeks.

If you live in Ontario or BC with public drug coverage: → Check if you meet formulary criteria (T2D, A1C >7.5-8.0%, metformin failure). If yes, pursue public coverage. Out-of-pocket will be $0-$50 CAD/month. → If you don't meet criteria, revert to the "no insurance" path above.

If you're considering medical tourism (buying in person in the U.S.): → Don't. U.S. pharmacy prices are higher than Canadian prices. The only scenario where this makes sense is if you're already traveling to the U.S. and can use a manufacturer coupon (which requires U.S. residency and insurance).

The math is straightforward: Canadian brand Mounjaro is cheaper than U.S. compounded at every dose when you account for exchange rates. The only reasons to choose U.S. compounded are (1) shortage-driven unavailability in Canada, or (2) preference for the bundled telehealth model.

What most articles get wrong about Canadian drug importation

Most articles on this topic claim that importing prescription medications from the U.S. to Canada is illegal. This is incorrect.

The confusion stems from conflating two different legal frameworks:

Framework 1: Commercial importation (illegal). Canadian law prohibits businesses from importing prescription drugs for resale without Health Canada approval. This is the rule that prevents Canadian pharmacies from buying drugs in the U.S. and reselling them in Canada. Violators face fines and criminal charges.

Framework 2: Personal importation (legal with conditions). Canadian law explicitly allows individuals to import prescription medications for personal use under the conditions listed earlier (90-day supply, valid prescription, non-controlled substance). This is codified in Health Canada's Personal Importation Policy (POL-0051).

The distinction matters because most articles cite the commercial importation prohibition and incorrectly apply it to individual patients. The result is that patients believe they're breaking the law when they're actually operating within a legal framework that Health Canada created specifically for this purpose.

The second common error: articles claim you need a Canadian prescription to import medications. You don't. You need a valid prescription from a licensed practitioner in the jurisdiction where the medication is dispensed. A U.S. prescription from a U.S. provider filled by a U.S. pharmacy satisfies this requirement.

The third error: articles claim Health Canada "doesn't recommend" personal importation, implying it's risky or quasi-legal. Health Canada's actual language is that "drugs purchased outside Canada may not meet Canadian safety standards." This is a safety disclaimer, not a legal prohibition. Health Canada doesn't recommend it for safety reasons (you're bypassing Canadian regulatory oversight), but they explicitly allow it legally.

Why does this matter? Because patients make decisions based on incorrect legal information and either (1) avoid a legal option that would save them money, or (2) proceed with unnecessary anxiety about legal risk that doesn't exist.

The accurate statement: Personal importation of prescription medications from the U.S. to Canada is legal under Health Canada's Personal Importation Policy, provided you meet the quantity and prescription requirements. It carries regulatory risk (the medication isn't Health Canada approved) but not legal risk (you're not breaking Canadian law).

FAQ

How much does Mounjaro cost per month in Canada without insurance? Mounjaro costs $300 to $415 CAD per month in Canada without insurance, depending on dose. The 2.5 mg starter dose costs $300 CAD, while the 15 mg maximum dose costs $415 CAD. Most patients maintain on 10 mg ($375 CAD) or 12.5 mg ($400 CAD).

Does Canadian health insurance cover Mounjaro? Private insurance covers Mounjaro when prescribed for type 2 diabetes in 85% of plans, typically at 60-80% coverage after prior authorization. Coverage for weight loss without diabetes is inconsistent. Provincial public plans in Ontario and BC cover Mounjaro for diabetes only, with strict criteria.

Is there a generic version of Mounjaro available in Canada? No. No generic tirzepatide is approved by Health Canada as of April 2026. Eli Lilly holds patent protection through 2036. The only alternatives are brand-name Mounjaro or compounded tirzepatide from U.S. sources.

Can I buy Mounjaro from a U.S. pharmacy and bring it to Canada? Yes, under Health Canada's personal importation policy. You can import up to a 90-day supply with a valid prescription for personal use. The prescription can be from a U.S. provider if the medication is dispensed by a U.S. pharmacy. Thousands of Canadians do this monthly.

Why is Mounjaro cheaper in Canada than the U.S.? Canada's Patented Medicine Prices Review Board regulates maximum prices for patented drugs. Eli Lilly set Mounjaro's Canadian price at $300-$415 CAD to comply with PMPRB guidelines. The U.S. has no federal price regulation, so Eli Lilly charges the list price of $1,069 USD.

Which Canadian provinces cover Mounjaro on public drug plans? Only Ontario and British Columbia list Mounjaro on provincial formularies as of April 2026. Both cover it for type 2 diabetes with A1C above 7.5-8.0% after metformin failure. Alberta is reviewing for potential listing in Q3 2026. Other provinces have not announced review timelines.

Is compounded tirzepatide from the U.S. cheaper than Canadian Mounjaro? No, in most cases. U.S. compounded tirzepatide costs $297-$399 USD ($407-$547 CAD converted), which is more expensive than Canadian brand Mounjaro at $300-$415 CAD. The exception is during Canadian shortages when brand Mounjaro is unavailable.

What doses of Mounjaro are currently unavailable in Canada? The 2.5 mg and 5 mg starter doses are on backorder as of April 2026, with expected resupply in May-June 2026. The 7.5 mg dose has intermittent availability. Doses of 10 mg and above are fully stocked.

Can my Canadian doctor prescribe compounded tirzepatide from a U.S. pharmacy? No. Canadian physicians cannot write prescriptions for U.S. pharmacies. You would need a consultation with a U.S.-licensed provider through a telehealth platform, who would then prescribe through a U.S. compounding pharmacy.

How much does Mounjaro cost at Costco vs Shoppers Drug Mart in Canada? Pricing is nearly identical across major chains. Costco, Shoppers Drug Mart, and Rexall all charge $300-$415 CAD depending on dose. Independent pharmacies sometimes charge $10-$20 more. Costco membership is not required to use Costco Pharmacy in Canada.

Does Mounjaro cost less in Mexico than Canada? Yes. Mounjaro costs approximately $180-$240 USD in Mexican pharmacies, which is 20-30% less than Canadian pricing. However, importing from Mexico to Canada requires the same personal importation rules (90-day supply, valid prescription). Most patients find U.S. compounded options more convenient than Mexican pharmacy logistics.

Will generic tirzepatide be available in Canada soon? Not until 2036 at the earliest. Eli Lilly's patent on tirzepatide expires in 2036. After expiry, generic manufacturers can apply for Health Canada approval, which typically takes 12-18 months. Realistically, generic tirzepatide won't reach the Canadian market before 2037-2038.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Health Canada Drug Product Database. Mounjaro (tirzepatide) Product Monograph. October 2022.
4. Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Tirzepatide (Mounjaro). September 2025.
5. Patented Medicine Prices Review Board. Annual Report 2025: Pricing Trends for Diabetes and Obesity Medications. 2025.
6. Health Canada. Personal Importation of Drugs Policy (POL-0051). Updated January 2024.
7. Canadian Life and Health Insurance Association. Survey of Private Drug Plan Coverage for GLP-1 Medications. 2025.
8. Drug Shortages Canada. Mounjaro (tirzepatide) Shortage Report. February 2026.
9. Ontario Ministry of Health. Ontario Drug Benefit Formulary: Limited Use Criteria for Tirzepatide. January 2026.
10. British Columbia Ministry of Health. PharmaCare Special Authority Criteria: Tirzepatide. March 2026.
11. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. January 2026.
12. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
13. Canada Border Services Agency. Importing Prescription Drugs for Personal Use: Guidelines. 2024.
14. Institut national d'excellence en santé et en services sociaux (INESSS). Drug Evaluation Pipeline Report. March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Shoppers Drug Mart, Rexall, and Costco are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.